Uwe Platzbecker, MD

Articles

Case 1: Expert Panelist Commentary

February 9th 2023

Expert panelists reflect on the case presented by Dr Garcia-Manero and share their unique perspectives on how they might have approached treatment and followup for this patient in their own practice.

Case 1 Presentation: Lower-Risk MDS with Multiple Chromosomal Abnormalities

February 2nd 2023

Guillermo Garcia-Manero, MD presents a case of lower-risk MDS with chromosome 5q and 20q deletions and a p53 mutation, and discusses first- and second-line treatment selection.

Second-Line Treatment Options for Lower-Risk MDS

February 2nd 2023

Dr Platzbecker outlines available second-line therapies for symptomatic anemia in patients with lower-risk MDS, highlighting differences in availability between the United States and Europe.

First-Line Treatment Options for Lower-Risk MDS

January 26th 2023

Thomas Cluzeau, MD, PhD provides an overview of first-line treatment options for symptomatic anemia in patients with lower-risk MDS, followed by a discussion of panelists’ treatment patterns and dosing strategies across the globe.

Considerations for MDS Pathology and Risk Status Reporting

January 26th 2023

A focused discussion on best practices for MDS pathology and risk status reporting in both community and academic center settings.

Tools for Risk Stratification and Prognosis in MDS

January 18th 2023

Uwe Platzbecker, MD introduces models commonly used to determine risk status and prognosis, and inform treatment decisions, for patients with MDS.

MDS: Typical Patient Presentation, Diagnostic Process, and Evolving Terminology

January 18th 2023

Moderator Rami Komrokji, MD, introduces the panel and invites expert pathologist Sanam Loghavi, MD to lead a discussion on the typical patient presentation and diagnostic process in MDS, which was recently renamed as ‘myelodysplastic neoplasms’ in the 2022 5th edition of the World Health Organization (WHO) classification of the disease state.

Imetelstat Achieved Prolonged, Continuous Transfusion Independence in Patients With Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis-Stimulating Agents Within the IMerge Phase 2 Study

December 22nd 2022

Dr Uwe Platzbecker reviews data on imetelstat in patients with lower-risk myelodysplastic syndromes (MDS) that were recently presented at the 2022 American Society of Hematology (ASH) Annual Meeting.